Galapagos, a clinical-stage biotech specializing in small molecule medicines, has dosed its first patient in its DIVERSITY (NCT02914561) Phase 3 clinical trial of filgotinib in Crohn’s disease. The trial is currently recruiting participants.
The initiation of the trial triggered a $50 million milestone payment from Gilead, the co-developer of filgotinib, a selective inhibitor of the JAK1 (Janus kinase 1), an enzyme involved in the signaling pathways of several pro-inflammatory cytokines, which ultimately lead to inflammation.
Filgotinib is the first JAK inhibitor to show effectiveness in Crohn’s, but it is still an investigational drug.
The Phase 3 trial’s primary objectives are to evaluate the drug’s effectiveness and safety in the induction and maintenance of remission in subjects with moderate-to-severe Crohn’s disease.
The DIVERSITY study will investigate two doses of filgotinib (100 mg and 200 mg) once-daily compared to a placebo in 1,230 patients, including those with prior biological therapy failure.
Participants who complete the study – or who do not meet protocol response or remission criteria at week 10 – will have the option to enter a separate long-term extension (LTE) study (NCT02914600).
“With the FITZROY Phase 2 study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn’s disease. The start of the Phase 3 DIVERSITY study is good news for patients with Crohn’s disease,” Piet Wigerinck, PhD, chief scientific officer of Galapagos, said in a press release. “We look forward to seeing the results of DIVERSITY.”
Galapagos and Gilead have a global collaboration agreement for the development and commercialization of filgotinib in inflammatory diseases.
In addition to the DIVERSITY trial, Gilead initiated the FINCH Phase 3 (NCT02873936) clinical program in rheumatoid arthritis in August this year, and is expected to start the SELECTION Phase 2b/3 trial (NCT02914522) in ulcerative colitis later this quarter. SELECTION will involve a futility analysis, which will serve as the Phase 2b part of the study.
Both DIVERSITY and SELECTION will recruit participants from the United States, Europe, Latin America, Canada and Asia/Pacific. In the U.S., men will be treated with 200 mg of filgotinib if they failed at least one anti-TNF (tumor necrosis factor) and Entyvio (vedolizumab). Testicular safety analyses will be included.
Subscribe to IBD News Today and receive our free, weekly newsletter directly in your email inbox so you’ll never miss another update again.
Print This Page
One comment